Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV study of bevacizumab plus interferon alfa-2a with molecular prognostic analysis in metastatic or advanced renal cancer
2009-014732-38Phase 4Active
- Sponsor
- SOGUG
- Start
- Jan 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bevacizumab and interferon alfa-2a in renal cell carcinoma (RCC), sponsored by SOGUG. Primary endpoint: Progression-free survival. Started Jan 2010; status: active.
02
Drugs
bevacizumabinterferon alfa-2a
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2009-014732-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014732-38.